Advertisement

Comment on “Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects”

  • Darías HolgadoEmail author
  • Thomas Zandonai
  • Daniel Sanabria
Letter to the Editor

Dear Editor,

We read with great interest the review by Heuberger and Cohen entitled “Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects” [1]. In general terms, the authors summarise well the current lack of sufficient empirical evidence regarding the substances and methods included in the World Anti-Doping Agency (WADA) Prohibited List. However, although the review is well focused in 2018, we believe further information about the status of tramadol in 2019 is required. We write this letter to provide additional insights into the status of tramadol in cycling.

On 21 June, 2018, L’Union Cicliste International announced that tramadol will be banned in competition from the 1 March, 2019 [2]. According to the most recent report available from WADA, 4.3% of urine and blood sample analyses from cyclists contained tramadol [3]. Despite the L’Union Cicliste International banning tramadol in competition, WADA intends to keep tramadol on the monitoring...

Notes

Compliance with Ethical Standards

Funding

Darias Holgado, Thomas Zandonai and Daniel Sanabria are supported by a grant from the World Anti-Doping Agency (reference 17C09DL). In addition, Daniel Sanabria is supported by grant PSI2016-75956-P from the Spanish Ministerio de Economía, Industria y Competitividad, and Darías Holgado is supported by grant FPU14/06229 from the Spanish Ministerio de Educación, Cultura y Deporte.

Conflict of interest

Darías Holgado, Thomas Zandonai and Daniel Sanabria have no conflicts of interest that are directly relevant to the content of this letter. The authors alone are responsible for the views expressed in this publication and they do not represent the decisions, policy or views of the World Anti-Doping Agency.

References

  1. 1.
    Heuberger JAAC, Cohen AF. Review of WADA prohibited substances: limited evidence for performance-enhancing effects. Sports Med. 2018;1:1.  https://doi.org/10.1007/s40279-018-1014-1.Google Scholar
  2. 2.
  3. 3.
    World Anti-Doping Agency. WADA publishes 2017 monitoring program figures (13 June 2018); 2018. https://www.wada-ama.org/en/media/news/2018-06/wada-publishes-2017-monitoring-program-figures. Accessed 11 Nov 2018.
  4. 4.
    World Anti-Doping Agency. The 2019 monitoring program; 2018. https://www.wada-ama.org/sites/default/files/wada_2019_french_monitoring_program.pdf. Accessed 23 Jan 2019.
  5. 5.
    Holgado D, Zandonai T, Zabala M, Hopker J, Perakakis P, Luque-Casado A, et al. Tramadol effects on physical performance and sustained attention during a 20-min indoor cycling time-trial: a randomised controlled trial. J Sci Med Sport. 2018;21:654–60.CrossRefGoogle Scholar
  6. 6.
    Beakley BD, Kaye AM, Kaye AD. Tramadol, pharmacology, side effects, and serotonin syndrome: a review. Pain Physician. 2015;18:395–400.Google Scholar
  7. 7.
    Nielsen B, Nybo L. Cerebral changes during exercise in the heat. Sports Med. 2003;33:1–11.CrossRefGoogle Scholar
  8. 8.
    Peng W, Hu Y, Mao Y, Babiloni C. Widespread cortical alpha-ERD accompanying visual oddball target stimuli is frequency but non-modality specific. Behav Res Med. 2015;295:71–7.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Mind, Brain and Behaviour Research CentreUniversity of Granada, Campus Universitario de Cartuja s/nGranadaSpain
  2. 2.Department of Physical Education and Sport, Faculty of Sport SciencesUniversity of GranadaGranadaSpain
  3. 3.Department of Experimental PsychologyUniversity of GranadaGranadaSpain

Personalised recommendations